|
1
|
Shulman AI and Mangelsdorf DJ: Retinoid ×
receptor heterodimers in the metabolic syndrome. N Engl J Med.
353:604–615. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tseng CH and Tseng FH: Peroxisome
proliferator-activated receptor agonists and bladder cancer:
lessons from animal studies. J Environ Sci Health C Environ
Carcinog Ecotoxicol Rev. 30:368–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kostapanos MS, Elisaf MS and Mikhailidis
DP: Pioglitazone and cancer: angel or demon? Curr Pharm Des.
19:4913–4929. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grygiel-Górniak B: Peroxisome
proliferator-activated receptors and their ligands: Nutritional and
clinical implications - a review. Nutr J. 13:172014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu YM and Woll PJ: Mitogenic effects of
interleukin-8/CXCL8 on cancer cells. Future Oncol. 1:699–704. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cui R, Qi Z, Zhou L, Li Z, Li Q and Zhang
J: Evaluation of serum lipid profile, body mass index, and
waistline in Chinese patients with type 2 diabetes mellitus. Clin
Interv Aging. 11:445–452. 2016.PubMed/NCBI
|
|
7
|
Lewis JD, Ferrara A, Peng T, Hedderson M,
Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J and
Strom BL: Risk of bladder cancer among diabetic patients treated
with pioglitazone: interim report of a longitudinal cohort study.
Diabetes Care. 34:916–922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsiao FY, Hsieh PH, Huang WF, Tsai YW and
Gau CS: Risk of bladder cancer in diabetic patients treated with
rosiglitazone or pioglitazone: a nested case - control study. Drug
Saf. 36:643–649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song SO, Kim KJ, Lee BW, Kang ES, Cha BS
and Lee HC: The risk of bladder cancer in korean diabetic subjects
treated with pioglitazone. Diabetes Metab J. 36:371–378. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Geisinger ML, Michalowicz BS, Hou W,
Schoenfeld E, Gelato M, Engebretson SP, Reddy MS and Hyman L:
Systemic inflammatory biomarkers and their association with
periodontal and diabetes-related factors in the diabetes and
periodontal therapy trial (DPTT), a randomized controlled trial. J
Periodontol. April 25–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Peng J, Sun W, Yang S, Deng G, Li
F, Cheng JW and Gordon JR: G31P, an antagonist against CXC
chemokine receptors 1 and 2, inhibits growth of human prostate
cancer cells in nude mice. Tohoku J Exp Med. 228:147–156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deng F, Wang J, Fan M, Guo Y, Li Y and Shi
Q: [Overexpression of IL-8 promotes migration of BT549 breast
cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:585–589.
2016.PubMed/NCBI
|
|
13
|
Lackner C, Jukic Z, Tsybrovskyy O, Jatzko
G, Wette V, Hoefler G, Klimpfinger M, Denk H and Zatloukal K:
Prognostic relevance of tumour-associated macrophages and von
Willebrand factor-positive microvessels in colorectal cancer.
Virchows Arch. 445:160–167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Infanger M, Kossmehl P, Shakibaei M,
Cogoli A, Witzing A, Faramarzi S, Wittfoht W, Paul M and Grimm D:
Vascular endothelial growth factor inhibits programmed cell death
of endothelial cells induced by clinorotation. J Gravit Physiol.
11:199–200. 2004.
|
|
15
|
Chodorowska G, Chodorowski J and
Wysokiński A: Vascular endothelial growth factor (VEGF) in
physiological and pathological conditions. Ann Univ Mariae Curie
Sklodowska Med. 59:8–14. 2004.PubMed/NCBI
|
